The global famciclovir market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Famciclovir is used to herpes zoster generally called shingle (a rash that can occur in people who have had chickenpox in the past). It’s also used to treat persons with a healthy immune system who have recurrent herpes virus cold sores or fever blisters. The herpes simplex virus causes cold sores. When this virus enters the body, it can cause cold sore outbreaks. Exposure to the scorching sun, chilly wind, a cold or another sickness, a weakened immune system, shifting hormone levels, or even worry can cause cold sore outbreaks. According to the report published by the National Health Portal in February 2021, Herpes caused by the herpes simplex virus (HSV) or herpes virus hominies, is one of the most common infections of humans across the globe. Further, according to the Hopkins Medicine Organization, around 80% of the total US population is suffering oral herps, which is leading cause for cold sores. Thus, such factors are anticipated to fuel the growth of the market globally.
Some major players in the market include Novartis International AG, Mylan N.V., Cipla Ltd., Hikma Pharmaceuticals plc, Teva Pharmaceutical Industries Ltd., among others. Th e market players are serving significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, in order to stay competitive in the market. For instance, in February 2019, Maruho and Asahi Kasei Pharma announce first approval in Japan of an additional dosage and administration for anti-herpes virus agent Famvir tab 250 mg” for the treatment of recurrent herpes simplex (herpes labialis/ herpes genitalis).
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Famciclovir Market at https://orionmarketreports.com/request-sample/?id=92682&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Novartis International AG, Mylan N.V., Cipla Ltd., Hikma Pharmaceuticals plc, Teva Pharmaceutical Industries Ltd., among others.
A full report is available at: https://orionmarketreports.com/global-famciclovir-market/92682/
Global Famciclovir Market Report by Segment
By Type
- 125 mg Tablets
- 250 mg Tablets
- 500 mg Tablets
By Application
- Cold Sores
- Genital Herpes
- Shingles
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
